A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease Patients

על הניסוי

The main goal of this phase llb study is to compare the efficacy and safety of two doses of HEC585 tablets with placebo which is a look-alike substance that contains no active drug in patients with progressive fibrosing interstitial lung diseases. This study is divided into two stages, i.e. main study stage with 24 weeks treatment duration followed by up to 96 weeks treatment extended study stage.

צפו ב-NCT05139719 ב-ClinicalTrials.gov ←

קישורים קשורים